Harrison LH, Pelton SI, Wilder-Smith A, Holst J, Safadi MA, Vazquez JA, et al. The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–71.

Article  PubMed  Google Scholar 

Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–11.

Article  PubMed  Google Scholar 

Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H, Nasiri MJ, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. Microb Pathog. 2019;134: 103571.

Article  PubMed  Google Scholar 

CDC. Revising the adolescent meningococcal vaccine schedule: Term of reference and considerations [online]. https://stacks.cdc.gov/view/cdc/148680. Accessed 12 Mar 2024.

CDC. Meningococcal disease: Surveillance [online]. https://www.cdc.gov/meningococcal/php/surveillance/. Accessed 12 Mar 2024.

Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010–2019: A literature review. Epidemiol Infect. 2023;151:e57.

Article  PubMed  PubMed Central  Google Scholar 

Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403.

Article  PubMed  Google Scholar 

Weil-Olivier C, Taha MK, Bouée S, Emery C, Loncle-Provot V, Nachbaur G, et al. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2022;18(1):2021764.

Article  PubMed  PubMed Central  Google Scholar 

Mbaeyi S, Duffy J, McNamara LA. Meningococcal Disease. CDC - The Pink Book; 2021.

Shen J, Begum N, Ruiz-Garcia Y, Martinon-Torres F, Bekkat-Berkani R, Meszaros K. Range of invasive meningococcal disease sequelae and health economic application—a systematic and clinical review. BMC Public Health. 2022;22(1):1078.

Article  PubMed  PubMed Central  Google Scholar 

Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin. 2011;7(4):458–65.

Article  PubMed  Google Scholar 

Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220–32.

Article  PubMed  Google Scholar 

Clark LJ, Glennie L, Audrey S, Hickman M, Trotter CL. The health, social and educational needs of children who have survived meningitis and septicaemia: the parents’ perspective. BMC Public Health. 2013;13:954.

Article  PubMed  PubMed Central  Google Scholar 

Shah HA, Herrera-Restrepo O, Jutlla G, et al. Market and non-market productivity losses associated with invasive meningococcal disease (IMD) in the United States (US). ESPID; May 20-24 2024; Copenhagen, Denmark.

Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, et al. Meningococcal vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41.

Article  PubMed  PubMed Central  Google Scholar 

CDC. ACIP recommendations [online]. 2023. https://www.cdc.gov/acip/vaccine-recommendations/. Accessed 12 Mar 2024.

Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, et al. National vaccination coverage among adolescents aged 13–17 years - National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(35):1101–8.

Article  PubMed  PubMed Central  Google Scholar 

Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659–74.

Article  CAS  PubMed  Google Scholar 

La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021;39(19):2660–7.

Article  PubMed  Google Scholar 

Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Sweeney C, et al. United States physicians' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults. J Adolesc Health. 2024;74(6):1131–8.

Herrera-Restrepo O, Zhou Z, Krishnan A, Conley WJ, Oladele E, Multani JK, et al. Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults. Curr Med Res Opin. 2024;40(1):125–40.

Article  CAS  PubMed  Google Scholar 

Basta NE, Becker AB, Li Q, Nederhoff D. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens. Vaccine. 2019;37(4):670–6.

Article  PubMed  Google Scholar 

Fergie J, Howard A, Huang L, Srivastava A. Implementation experience with meningococcal serogroup B vaccines in the United States: Impact of a nonroutine recommendation. Pediatr Infect Dis J. 2021;40(3):269–75.

Article  PubMed  Google Scholar 

Schillie SF. Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination. 2024. https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/04-Mening-Schillie-508.pdf. Accessed 20 Aug 2024.

CDC. Enhanced meningococcal disease surveillance report, 2021 [online]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf. Accessed 12 Mar 2024.

Wang B, Marshall HS. A new era for equity in meningococcal disease prevention. Lancet Infect Dis. 2023;23(12):1329–30.

Article  PubMed  Google Scholar 

Beck E, Klint J, Garcia S, Abbing V, Abitbol V, Akerborg O, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England. Vaccine. 2020;38(47):7558–68.

Article  PubMed  Google Scholar 

Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91–104.

Article  PubMed  Google Scholar 

Mbaeyi S, Pondo T, Blain A, Yankey D, Potts C, Cohn A, et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 2020;174(9):843–51.

Article  PubMed  Google Scholar 

Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college—Rhode Island, 2015–2016. Clin Infect Dis. 2017;64(8):1115–22.

Article  CAS  PubMed  Google Scholar 

Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649.e1-e8.

Article  CAS  PubMed  Google Scholar 

Biolchi A, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2021;10(1):307–16.

Article  PubMed  Google Scholar 

Castilla J, García Cenoz M, Abad R, Sánchez-Cambronero L, Lorusso N, Izquierdo C, et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388(5):427–38.

Article  CAS  PubMed  Google Scholar 

MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–6.

Article  PubMed  Google Scholar 

Packnett ER, Zimmerman NM, Kim G, Novy P, Morgan LC, Chime N, et al. A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States. Pediatr Infect Dis J. 2022;41(4):e158–65.

Article  PubMed  PubMed Central  Google Scholar 

Ortega-Sanchez IR. The cost-effectiveness of a potential pentavalent meningococcal conjugate vaccine (Men ABCWY) versus the current Men ACWY and Men B vaccines for US adolescents. 2023. https://www.cdc.gov/acip/downloads/slides-2023-06-21-23/02-Mening-Ortega-Sanchez-508.pdf. Accessed 12 Mar 2024.

CDC. Economics of Potential Pentavalent Meningococcal Conjugate Vaccine (MenABCWY) versus the Current MenACWY and MenB vaccines for US Adolescents [online]. https://www.cdc.gov/acip/downloads/slides-2023-10-25-26/03-Meningococcal-Ortega-Sanchez-508.pdf. Accessed 4 Apr 2024.

CDC. GSK pentavalent MenABCWY vaccine: Term of reference [online]. https://www.cdc.gov/acip/downloads/slides-2024-02-28-29/03-Meningitis-Schillie-508.pdf. Accessed 4 Apr 2024.

Huang L, Snedecor SJ, Balmer P, Srivastava A. Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States. Postgrad Med. 2022;134(4):341–8.

Article  CAS  PubMed  Google Scholar 

US Census Bureau. US population by age: Single year age groups [online]. 2015.